The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
This is used to treat central diabetes insipidus and bedwetting
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Subscribe To Our Newsletter & Stay Updated
